Evidence map›Paper›PMID 38897709›Full record

ReviewAdvances in virus research2024

Uncloaking the viral glycocalyx: How do viruses exploit glycoimmune checkpoints?

Anthony J Domma, Lauren A Henderson, Jeffery A Nurdin, Jeremy P Kamil

Abstract readReview
In one paragraph

Review in Advances in virus research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anthony J DommaLSU Health Sciences Center at Shreveport, Shreveport, LA, United States.
Lauren A HendersonLSU Health Sciences Center at Shreveport, Shreveport, LA, United States.
Jeffery A NurdinLSU Health Sciences Center at Shreveport, Shreveport, LA, United States.
Jeremy P KamilLSU Health Sciences Center at Shreveport, Shreveport, LA, United States. Electronic address: jeremy.kamil@lsuhs.edu.

Funding

Project 4-Tracking cytomegalovirus-primed long-lived NK cells in salivary glandP20GM134974 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ANDREW D YUROCHKO · 2021 to 2026
$15.0M
Roles of the UL148 glycoprotein in human cytomegalovirus infectionR01AI116851 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jeremy Phillip Kamil · 2016 to 2026
$3.5M
Multidisciplinary Training in Cardiovascular PathophysiologyT32HL155022 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE, STOKES, KAREN Y · 2021 to 2025
$619k
NHLBI NIH HHS T32 HL155022NIAID NIH HHS R01 AI116851NIGMS NIH HHS P20 GM134974
6 · The paper itself

Abstract

The surfaces of cells and enveloped viruses alike are coated in carbohydrates that play multifarious roles in infection and immunity. Organisms across all kingdoms of life make use of a diverse set of monosaccharide subunits, glycosidic linkages, and branching patterns to encode information within glycans. Accordingly, sugar-patterning enzymes and glycan binding proteins play integral roles in cell and organismal biology, ranging from glycoprotein quality control within the endoplasmic reticulum to lymphocyte migration, coagulation, inflammation, and tissue homeostasis. Unsurprisingly, genes involved in generating and recognizing oligosaccharide patterns are playgrounds for evolutionary conflicts that abound in cross-species interactions, exemplified by the myriad plant lectins that function as toxins. In vertebrates, glycans bearing acidic nine-carbon sugars called sialic acids are key regulators of immune responses. Various bacterial and fungal pathogens adorn their cells in sialic acids that either mimic their hosts' or are stolen from them. Yet, how viruses commandeer host sugar-patterning enzymes to thwart immune responses remains poorly studied. Here, we review examples of viruses that interact with sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immune cell receptors that regulate toll-like receptor signaling and govern glycoimmune checkpoints, while highlighting knowledge gaps that merit investigation. Efforts to illuminate how viruses leverage glycan-dependent checkpoints may translate into new clinical treatments that uncloak viral antigens and infected cell surfaces by removing or masking immunosuppressive sialoglycans, or by inhibiting viral gene products that induce their biosynthesis. Such approaches may hold the potential to unleash the immune system to clear long intractable chronic viral infections.

Indexed as

GlycocalyxVirusesAnimalsHost-Pathogen InteractionsHumansPolysaccharidesSialic Acid Binding Immunoglobulin-like LectinsVirus DiseasesPolysaccharidesSialic Acid Binding Immunoglobulin-like LectinsChronic infectionGlycobiologyGlycoimmune checkpointsImmune checkpointsImmunityNeuraminic acidsSialic acidSialoglycanSiglec

Identifiers

PMID38897709
PMCPMC11192240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.